Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of Votoplam in Huntington's disease
NL-OMON61010Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of votoplam in Huntington disease (HD), sponsored by Novartis. Primary endpoints: Long-term safety profile and Blood total huntingtin levels. Started Nov 2023; status: active, not recruiting.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON61010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61010.